Literature DB >> 18796378

Drug-related hepatotoxicity and hepatic failure following combined androgen blockade.

Inmaculada Castro Beza1, Jesús Sánchez Ruiz, Francisco José Peracaula Espino, M Isabel Villanego Beltrán.   

Abstract

Androgen deprivation therapy has been the mainstay of treatment for metastatic prostate cancer and of less advanced cancers as neoadjuvant and adjuvant treatment. Abnormal liver function test, in particular elevated transaminases, is an adverse reaction more frequently noticed during androgen deprivation therapy with antiandrogen. We report the case of a patient with acute hepatic failure associated with the use of bicalutamide.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18796378     DOI： 10.1007/s12094-008-0256-5

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  7 in total

Review 1.  Criteria of drug-induced liver disorders. Report of an international consensus meeting.

Authors:  C Bénichou
Journal:  J Hepatol       Date:  1990-09       Impact factor: 25.083

Review 2.  Drug-related hepatotoxicity.

Authors:  Victor J Navarro; John R Senior
Journal:  N Engl J Med       Date:  2006-02-16       Impact factor: 91.245

3.  Fulminant hepatic failure associated with bicalutamide.

Authors:  L A Dawson; E Chow; G Morton
Journal:  Urology       Date:  1997-02       Impact factor: 2.649

4.  Current clinical studies with a new nonsteroidal antiandrogen, Casodex.

Authors:  A V Kaisary
Journal:  Prostate Suppl       Date:  1994

5.  A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.

Authors:  P F Schellhammer; R Sharifi; N L Block; M S Soloway; P M Venner; A L Patterson; M F Sarosdy; N J Vogelzang; Y Chen; G J Kolvenbag
Journal:  Cancer       Date:  1996-11-15       Impact factor: 6.860

6.  Fatal and nonfatal hepatotoxicity associated with flutamide.

Authors:  D K Wysowski; J P Freiman; J B Tourtelot; M L Horton
Journal:  Ann Intern Med       Date:  1993-06-01       Impact factor: 25.391

7.  [Fatal fulminant hepatitis induced by nilutamide (Anandron)].

Authors:  P Pescatore; P Hammel; F Durand; P Bertheau; J Bernuau; D Huc; J L Gerbal; C Degott; J P Benhamou
Journal:  Gastroenterol Clin Biol       Date:  1993
  7 in total
  4 in total

1.  Atypical onset of bicalutamide-induced liver injury.

Authors:  Gee Young Yun; Seok Hyun Kim; Seok Won Kim; Jong Seok Joo; Ju Seok Kim; Eaum Seok Lee; Byung Seok Lee; Sun Hyoung Kang; Hee Seok Moon; Jae Kyu Sung; Heon Young Lee; Kyung Hee Kim
Journal:  World J Gastroenterol       Date:  2016-04-21       Impact factor: 5.742

2.  Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma.

Authors:  Jianhua Li; Xinguang Qiu; Wenzhi Guo; Bing Yan; Shuijun Zhang
Journal:  Med Oncol       Date:  2015-09-02       Impact factor: 3.064

3.  Bicalutamide-induced hepatotoxicity: A rare adverse effect.

Authors:  Salwa Hussain; Abdallah Haidar; Robert E Bloom; Nafea Zayouna; Michael H Piper; Syed-Mohammed R Jafri
Journal:  Am J Case Rep       Date:  2014-06-20

4.  Efficiency and safety evaluation of prophylaxes for venous thrombosis after gynecological surgery.

Authors:  Ruidi Yu; Faridah Nansubuga; Jun Yang; Wencheng Ding; Kezhen Li; Danhui Weng; Peng Wu; Gang Chen; Ding Ma; Juncheng Wei
Journal:  Medicine (Baltimore)       Date:  2020-06-19       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.